Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Rosneft reports for 2023 by IFRS

2/19/24 ROSN

VK Dating launched in Belarus

2/19/24 VKCO

Delimobile launched Deliclub for shareholders

2/19/24 DELI

Board of Directors of Cherkizovo Group recommended that dividends be paid for 2023

2/19/24 GCHE

Samolet has appointed a new head of the company

2/19/24 SMLT

Unipro reported for 2023 by IFRS

2/19/24 UPRO

Tinkoff Bank entered Crimea

2/19/24 T

Kamaz will increase production up to 220 trucks per day

2/19/24 KMAZ

Polymetal postpones dividend decision until May for now

2/19/24 POLY

UGC will free up more than 40 tons of gold for mining

2/19/24 UGLD